REGN: Strong growth in Dupixent and EYLEA HD, with new launches and pipeline assets driving future momentum
Dupixent continues to drive growth with strong performance across multiple indications and high adherence, while new pipeline assets and strategic collaborations aim to sustain leadership in immunology. Cemdisiran is poised for launch in myasthenia gravis, and EYLEA HD maintains momentum amid upcom…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.